Botensilimab and balstilimab combination therapy is approved in France for ovarian cancers and soft tissue sarcomas under the AAC framework. The therapy, initially for microsatellite-stable metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results